




Eurofins Pharma Services

Eurofins Medigenomix GmbH – Professional Partner
in Pharmacogenetics and Pharmacogenomics

New Screening Service for preclinical research: the OncoCarta™ Panel




Eurofins Medigenomix GmbH extended their broad pharma services portfolio by addition of the OncoCarta™ Panel* from *Sequenom Inc., San Diego, CA*. Using the OncoCarta™ Panel a comprehensive somatic mutation profiling is possible. In addition to the characterisation of cell lines, the OncoCarta™ Panel can also be



used for screening of clinical relevant mutations in tumor samples in the scope of drug development. With the panel it is possible to analyse up to 238 relevant mutations in 19 oncogenes, e.g. in EGFR, KRAS or BRAF.



As starting material for example fresh, frozen or formalin-fixed paraffin-embedded (FFPE) tumor tissue can be used. Analyses with the OncoCarta™ Panels are carried out on the MALDI-TOF mass spectrometry platform MassARRAY® from Sequenom.



The main advantages of these panels are:

- Extreme sensitivity: Mutations occurring at down to 10% frequency can be detected and are reliably quantified
- DNA from FFPE samples can be used as starting material
- Only 500 ng of genomic DNA are required per analysis.

Please contact us to discuss your project or your study in detail:
pharmacogenetics@medigenomix.de

*for research use only